Dr. Salani on the Rationale for Immunotherapy/PARP Inhibitor Combos in Ovarian Cancer


In Partnership With:

Ritu Salani, MD, MBA, discusses the rationale for combinations of immunotherapy and PARP inhibitors in ovarian cancer.

Ritu Salani, MD, MBA, director of the Division of Gynecologic Oncology, professor of Obstetrics and Gynecology, University of California, Los Angeles, discusses the rationale for combinations of immunotherapy and PARP inhibitors in ovarian cancer.

Combination immunotherapy and PARP inhibitors capitalize on DNA damage repair and priming the immune system and in turn, the immunotherapy can be more active in tumors that are not typically considered immunogenic, Salani says. Overall, immunotherapy can exploit a deficiency to make it opportunistic. 

Preliminary data observed in phase 2 clinical trials have suggested utility with this combination approach, Salani explains.

Moreover, adding VEGF inhibitors, such as bevacizumab (Avastin), to this combination strategy could enhance synergistic activity of this treatment for patients with ovarian cancer independent of BRCA, homologous recombination deficiency, or PD-1/PD-L1 status, Salani concludes.

Related Videos
Petros Grivas, MD, PhD, professor, Clinical Research Division, Fred Hutchinson Cancer Center; professor, Division of Hematology and Oncology, University of Washington (UW) School of Medicine; clinical director, Genitourinary Cancers Program, UW Medicine
Somedeb Ball, MBBS, assistant professor, medicine, Division of Hematology Oncology, Department of Medicine, Vanderbilt University Medical Center
Phillip J. Koo, MD
Gabriella Smith, MD
Mikkael A. Sekeres, MD, MS
Francesco Di Meo, PhD
Ko Un “Clara” Park, MD
Naseema Gangat, MBBS
Erin Frances Cobain, MD
Pashtoon Murtaza Kasi, MD, MS